Edwards Lifesciences Sets 52-Week High as Analysts Lift Price Targets

Edwards Lifesciences Corporation shares climbed to a new 52-week peak of $105.63 during mid-day trading on Wednesday. The move followed a price target increase from TD Cowen, which lifted its objective on the medical technology company from $117.00 to $121.00 while maintaining a buy rating. The stock, which had previously closed at $104.01, traded as high as $105.63 before last changing hands at $105.6550.

The advance comes after Edwards Lifesciences reported quarterly financial results on Wednesday, November 4th. The firm posted earnings of $0.80 per share, surpassing consensus expectations of $0.74 per share. Revenue reached $1.72 billion, topping the projected $1.68 billion and expanding 10.5% compared to the same period in the prior year. Sales growth was aided by a 45.6% increase in transcatheter mitral and tricuspid therapies (TMTT) and an 8.8% rise in transcatheter aortic valve replacement (TAVR) revenue. The company also raised its sales outlook and established adjusted full-year earnings guidance between $2.97 and $3.05 per share.

In addition to quarterly gains, clinical data provided support. Findings from the PROGRESS Trial demonstrated that TAVR delivered superior outcomes compared with active surveillance for at-risk patients suffering from moderate aortic stenosis, yielding fewer combined death or heart-failure events. The study could justify earlier use of the treatment and expand the addressable patient base, though company leadership has also noted that rising competition in TAVR could pressure future growth and market share.

Wall Street has responded with a wave of target revisions. UBS Group lifted its target price to $118.00, Citigroup pushed its objective to $117.00, and Barclays raised its target to $120.00. Additional firms including Piper Sandler, Leerink Partners, Mizuho, and Wells Fargo also reiterated positive ratings and raised expectations. Across the street, 23 analysts evaluate the stock as a Buy while three maintain a Hold rating, yielding a consensus Moderate Buy rating and average targets near $108.88 and $109.56, according to MarketBeat.

Meanwhile, regulatory filings revealed recent insider selling. Vice President Donald E. Bobo, Jr. sold 48,900 shares on Monday, November 9th, at an average price of $103.05 for $5,039,145.00 through a pre-arranged Rule 10b5-1 trading plan. Several other executives also executed planned sales earlier in the year. Separately, institutional investors adjusted their positions, with Lockheed Martin Investment Management Co. cutting its stake by 31.3% and Candriam S.C.A. trimming its holdings by 44.1% during the third quarter.